statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why Vaxxinity Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day Session

Presentation will address the Company's clinical data in Parkinson's diseaseCAPE CANAVERAL, Fla., March 28, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the...

Vaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meeting

CAPE CANAVERAL, Fla., March 27, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of immunotherapeutic vaccines, today reported...

Vaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate Updates

Vaxxinity, Inc. (NASDAQ:VAXX  Get Free Report) shares dropped 4.5% during trading on Monday . The company traded as low as $0.71 and last traded at $0.72. Approximately 195,541 shares changed...

Vaxxinity (NASDAQ:VAXX)  Shares Down 4.5%

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Vaxxinity announces 'positive' target engagement data from Phase 1 trial

UB-312 is first immunotherapy to show reduction of pathological alpha-synuclein in cerebrospinal fluid of Parkinson's patientsLISBON, Portugal, March 07, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc...

Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson's Disease at AD/PD  2024

Key Insights The considerable ownership by private companies in Vaxxinity indicates that they collectively have a...

Private companies in Vaxxinity, Inc. (NASDAQ:VAXX) are its biggest bettors, and their bets paid off as stock gained 22% last week

Preclinical data published in the Journal of Lipid Research indicate VXX-401 is well-tolerated, with no safety signals observed, and robustly reduces LDL-C in cynomolgus monkeys. A Phase 1 trial of...

Vaxxinity's Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Published

CAPE CANAVERAL, Fla., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced it will present...

Vaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024

CAPE CANAVERAL, Fla., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced a research...

Vaxxinity Announces Research Collaboration on Active Immunotherapies for Neurodegenerative Diseases with University of Florida

Vaxxinity, Inc. is a biotechnology company that aims to democratize health by bringing the efficiency of vaccines to chronic diseases. The company uses its synthetic peptide vaccine platform to harness the immune system and convert the body into its own 'drug factory', stimulating the production of antibodies with a therapeutic effect. Its current pipeline consists of five chronic disease candidates from early to late-stage development across multiple therapeutic areas including Alzheimer’s, Parkinson’s, migraine and hypercholesterolemia as well as a candidate for COVID-19 prevention. The company was founded by Louis G. Reese IV and Mei Mei Hu in 2014 and is headquartered in Exploration Park, FL.

Watchers	1,339
52-Wk Low	$0.0453
52-Wk High	$3.10

Volume	443,712.00
52-Wk High	$3.10
52-Wk Low	$0.0453

Period	Estimated	Reported	Surprise	Result
Q4'23	-$0.10	-$0.09	10.00%	BEAT
Q3'23	-$0.11	-$0.10	9.09%	BEAT
Q2'23	-$0.16	-$0.11	29.03%	BEAT
Q1'23	-$0.15	-$0.15	--	EXPECTED
Q4'22	-$0.16	-$0.16	--	EXPECTED

VAXX Vaxxinity Inc - Ordinary Shares - Class A

About

Feed

News

Earnings

Fundamentals